Motac (Esters Of Unsaturated Fatty Acids)

The esters of unsaturated fatty acids in Motac are hydrolyzed to free fatty acids that can be incorporated into cell membranes and serve as precursors for bioactive lipid mediators. These actions may affect membrane fluidity, signaling cascades, and metabolic processes, although the exact mechanisms in humans remain under study.

The dosage of Motac is determined by the prescribing clinician or the study protocol. Because the product is used mainly in investigational settings, the prescriber sets the appropriate amount based on the specific research objectives, patient characteristics and regulatory guidance.

Safety data for Motac in pregnant or lactating individuals are insufficient. Until robust clinical evidence is available, it is generally recommended to avoid use during pregnancy and breastfeeding unless the potential benefits outweigh the unknown risks and a qualified healthcare professional provides explicit guidance.

To place an order, submit an enquiry on the Motac product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Motac provides esters of unsaturated fatty acids in a form intended for investigational use, whereas other fatty‑acid products may be marketed as dietary supplements or as part of approved pharmaceuticals. Unlike supplements, Motac is supplied under GMP conditions for research, and its purity, concentration and regulatory status differ from over‑the‑counter alternatives.

Motac should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. The container should remain tightly closed, and any unused portion should be kept in a dry, cool environment to maintain product stability.

Motac is formulated for oral administration. The product is typically taken with water, and the exact method of ingestion (e.g., with or without food) should follow the instructions provided by the prescribing investigator or the study protocol.

Serious risks, although rarely reported, may include allergic hypersensitivity reactions, significant liver enzyme elevations and severe skin eruptions. Patients should be monitored for any signs of these events, and treatment should be discontinued immediately if such reactions occur.

Motac should be avoided in individuals with known hypersensitivity to unsaturated fatty acid esters, in patients with active liver disease without close monitoring, and in anyone participating in a study where the investigational product is contraindicated by the protocol. Use in pregnant or breastfeeding women is also discouraged pending further safety data.